Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai’s Halaven Clinches NICE OK as 3rd-Line Breast Cancer Therapy
November 7, 2016
- Mitsubishi Tanabe to Offer Compound Library to Univ. of Tokyo
November 7, 2016
- Acne Med Epiduo Gel Hits Japan Shelves: Maruho
November 7, 2016
- JCR to Provide Temcell for IIT in Epidermolysis Bullosa
November 4, 2016
- Santen Profits Tumble Over 70% on Strong Yen, Divestment; Ophthalmology Biz Brisk
November 4, 2016
- Pfizer Japan Calls Off Transfer of Innovative Drugs after Global Split Plan Scrapped
November 4, 2016
- Mitsubishi Tanabe Licenses Cell Therapy Agent for Knee Osteoarthritis from S. Korean Firm
November 4, 2016
- Mitsubishi Tanabe Ekes Out Sales Rise on Simponi, Other Major Products
November 2, 2016
- Harvoni Top-Seller Drug in Japan in July-September: QuintilesIMS
November 2, 2016
- Strong Yen Dampens Sales of 4 Japanese Majors, but Global Brands Keep Up Momentum
November 2, 2016
- HER2-Targeting ADC Is One of Our Top Priorities: Daiichi Sankyo CEO
November 2, 2016
- Eisai’s Midterm Strategy Focusing on Neurology, Oncology “Gradually Producing Results”: CEO Naito
November 2, 2016
- Shionogi Shooting for New Product Sales of 200 Billion Yen in FY2020
November 2, 2016
- Takeda Establishes Drug Discovery Company in New York in Partnership with US Research Institutions
November 2, 2016
- Hisaharu Hirai Named as Japan Vaccine Chairman
November 2, 2016
- Merck Serono Aims to Get Japan Nod for Avelumab in 2017: Pres. Lee
November 2, 2016
- Takeda Mum on Kaketsuken Biz Transfer; CEO Says He Needs to Better Understand Situation
November 1, 2016
- MSD Files Japan NDA for Bezlotoxumab for C. Difficile Infection
November 1, 2016
- Pfizer Seeks Japan Approval of Breast Cancer Drug Palbociclib
November 1, 2016
- Eisai’s BACE Inhibitor Enters PIII, Enrollment Begins in US
November 1, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…